Search

Your search keyword '"Tao, Kaixiong"' showing total 916 results
Start Over Author "Tao, Kaixiong"
916 results on '"Tao, Kaixiong"'

21. CACA guidelines for holistic integrative management of rectal cancer

Author

Wang, Guiyu, Fan, Daiming, Gu, Jin, Ding, Kefeng, Fang, Xuedong, Shen, Lin, Xu, Zhongfa, Xu, Jianmin, Cai, Jianchun, Cai, Lianming, Cai, Sanjun, Chen, Gong, Chen, Jiansi, Cheng, Longwei, Cheng, Yong, Chi, Pan, Cui, Binbin, Dai, Guanghai, Fu, Chuangang, Gu, Yanhong, He, Guodong, Hu, Junhong, Huang, Jing, Huang, Rui, Huang, Zhongcheng, Jiang, Zheng, Jie, Zhigang, Ju, Haixing, Li, Hai, Li, Jian, Li, Jun, Li, Ming, Li, Yaoping, Li, Yunfeng, Lin, Guole, Liu, Haiying, Liu, Ming, Liu, Qian, Pan, Zhizhong, Peng, Yifan, Qian, Niansong, Qiu, Meng, Ren, Li, Sun, Yueming, Tang, Jianqiang, Tang, Qingchao, Tang, Yuan, Tao, Kaixiong, Tao, Min, Wang, Haijiang, Wang, Meng, Wang, Zejun, Wang, Zhengguang, Wang, Ziqiang, Wang, Ziwei, Wei, Shaozhong, Xing, Baocai, Xiong, Bin, Xu, Ye, Yan, Su, Yang, Bin, Yang, Chunkang, Yao, Qinghua, Ye, Yingjiang, Yuan, Ying, Zhang, Guozhi, Zhang, Haizeng, Zhang, Hongmei, Zhang, Zhen, Zhong, Yunshi, Zhu, Ji, Zhu, Yuan, Zhu, Yuping, Zou, Shuangmei, Wang, Yuliuming, Lv, Jingfang, Liu, Enrui, Yang, Ming, Zhang, Qian, Zhang, Weiyuan, Zhang, Lin, Luo, Jun, Zheng, Zhaoxu, Zhao, Zhixun, Liu, Zheng, Tao, Jinhua, Huang, Haiyang, Chen, Tianli, and Wang, Xishan

Published
2023
Full Text
View/download PDF

22. Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China

Author

Li, Jian, Zhang, Jun, Zhang, Yanqiao, Qiu, Haibo, Zhou, Yanbing, Zhou, Yongjian, Zhang, Xinhua, Zhou, Ye, Zhu, Yuping, Li, Yong, Wang, Ming, Shen, Kuntang, Tao, Kaixiong, Wu, Xin, Wang, Haijiang, Zhang, Bo, Ling, Jiayu, Ye, Yingjiang, Wu, Xingye, Qu, Hongyan, Ma, Yue, Jiao, Xuelong, Zheng, Hualong, Jin, Jiejie, Liu, Zhuo, Tan, Ming, Fang, Yong, Zhang, Peng, Zhang, Nan, Lei, Cheng, Cai, Zhaolun, Liang, Bin, Peng, Zhangyan, Huang, Zhao, Dong, Juan, and Shen, Lin

Published
2024
Full Text
View/download PDF

30. METTL16 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in pancreatic ductal adenocarcinoma

Author

Zeng, Xiangyu, Zhao, Fei, Cui, Gaofeng, Zhang, Yong, Deshpande, Rajashree A., Chen, Yuping, Deng, Min, Kloeber, Jake A., Shi, Yu, Zhou, Qin, Zhang, Chao, Hou, Jing, Kim, Wootae, Tu, Xinyi, Yan, Yuanliang, Xu, Zhijie, Chen, Lifeng, Gao, Huanyao, Guo, Guijie, Liu, Jiaqi, Zhu, Qian, Cao, Yueyu, Huang, Jinzhou, Wu, Zheming, Zhu, Shouhai, Yin, Ping, Luo, Kuntian, Mer, Georges, Paull, Tanya T., Yuan, Jian, Tao, Kaixiong, and Lou, Zhenkun

Published
2022
Full Text
View/download PDF

36. HER2 becomes a novel survival biomarker for gastric cancer patients: a pooled analysis.

Author

Cheng, Ji, Cai, Ming, Wang, Guobin, and Tao, Kaixiong

Abstract

Background: Although anti-HER2 therapies have been widely used against gastric carcinoma, the prognostic significance of HER2 overexpression remains unclear. Previous studies failed to provide convincible evidence due to inconsistent HER2 evaluation criteria and heterogeneous clinical characteristics. Objectives: To figure out the prognostic significance of HER2 expression in gastric cancer, we rigorously designed and conducted this study. Design: Meta-analysis. Data sources and methods: Record retrieval was performed by searching PubMed, Web of Science, Cochrane Library, Embase, ASCO, and ESMO meeting libraries from inception to November 2022. Cohort studies investigating overall survival comparison between HER2-positive and HER2-negative gastric cancer patients were included. Both resectable and advanced cases were separately collected while HER2 evaluation standards should be consistent across eligible studies. Newcastle–Ottawa Scale was used for quality assessment. Overall survival was the only endpoint and effect size was presented by hazard ratio (HR) with its 95% confidence interval. The pooled calculation was conducted on Review Manager 5.4. Results: Thirty studies were eligible, including 9945 patients. Eligible studies were mostly high quality (n = 31). Regarding resectable cases (n = 22), HER2-positive groups had significantly worse prognosis than HER2-negative counterparts (HR 1.56, 95%CI 1.32–1.85, p < 0.00001). For HER2-positive patients with advanced gastric cancer (n = 10), HER2 overexpression was also an unfavorable survival indicator (HR 1.70, 95%CI 1.23–2.35, p = 0.001). Potential heterogeneous studies had been eliminated while outcomes remained stable by sensitivity analysis. Subgroup analysis suggested HER2-positive patients had a poorer prognosis in both East Asian (resectable: HR 1.56; advanced: HR 1.32) and non-East Asian countries (HR 1.58; HR 3.27). Conclusion: As a novel survival biomarker in gastric cancer, HER2 overexpression indicates unfavorable prognosis among both resectable and advanced patients, irrespective of East Asian or non-East Asian populations. Trial registration: PROSPERO (CRD42020168051). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Robotic colorectal cancer surgery in China: a nationwide retrospective observational study

Author

Xu, Jianmin, Tang, Bo, Li, Taiyuan, Jia, Baoqing, Yao, Hongliang, Zhao, Ren, Yuan, Weitang, Zhong, Ming, Chi, Pan, Zhou, Yanbing, Yang, Xiongfei, Cheng, Longwei, He, Yulong, Li, Yongxiang, Tong, Weidong, Sun, Xuejun, Jiang, Zhiwei, Wang, Kang, Li, Xiaorong, Wang, Xin, Wei, Ye, Chen, Zongyou, Zhang, Xiaoqiao, Ye, Yingjiang, Han, Fanghai, Tao, Kaixiong, Kong, Dalu, Wang, Ziqiang, Zhang, Cheng, He, Guodong, and Feng, Qingyang

Published
2021
Full Text
View/download PDF

38. Machine learning based peri-surgical risk calculator for abdominal related emergency general surgery: a multicenter retrospective study

Author

Chen, Biao, primary, Sheng, Weiyong, additional, Wu, Zhixin, additional, Ma, Bingqing, additional, Cao, Nan, additional, Li, Xushu, additional, Yang, Jia, additional, Yuan, Xiaowei, additional, Yan, Lizhao, additional, Zhu, Gaobo, additional, Zhou, Yuanhong, additional, Huang, Zhonghua, additional, Zhu, Meiwei, additional, Ding, Xuehui, additional, Du, Hansong, additional, Wan, Yanqing, additional, Gao, Xuan, additional, Cheng, Xing, additional, Xu, Peng, additional, Zhang, Teng, additional, Tao, Kaixiong, additional, Shuai, Xiaoming, additional, Cheng, Ping, additional, Gao, Yong, additional, and Zhang, Jinxiang, additional

Published
2024
Full Text
View/download PDF

40. Supplementary Table S1 from Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies

Author

Heinrich, Michael C., primary, Zhang, Xinhua, primary, Jones, Robin L., primary, George, Suzanne, primary, Serrano, César, primary, Deng, Yanhong, primary, Bauer, Sebastian, primary, Cai, Shirong, primary, Wu, Xin, primary, Zhou, Yongjian, primary, Tao, Kaixiong, primary, Zheng, Zhichao, primary, Zhang, Jun, primary, Cui, Yuehong, primary, Cao, Hui, primary, Wang, Meining, primary, Hu, Jin, primary, Yang, Jason, primary, Li, Jian, primary, and Shen, Lin, primary

Published
2024
Full Text
View/download PDF

41. Supplementary Figure S1 from Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies

Author

Heinrich, Michael C., primary, Zhang, Xinhua, primary, Jones, Robin L., primary, George, Suzanne, primary, Serrano, César, primary, Deng, Yanhong, primary, Bauer, Sebastian, primary, Cai, Shirong, primary, Wu, Xin, primary, Zhou, Yongjian, primary, Tao, Kaixiong, primary, Zheng, Zhichao, primary, Zhang, Jun, primary, Cui, Yuehong, primary, Cao, Hui, primary, Wang, Meining, primary, Hu, Jin, primary, Yang, Jason, primary, Li, Jian, primary, and Shen, Lin, primary

Published
2024
Full Text
View/download PDF

42. Data from Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies

Author

Heinrich, Michael C., primary, Zhang, Xinhua, primary, Jones, Robin L., primary, George, Suzanne, primary, Serrano, César, primary, Deng, Yanhong, primary, Bauer, Sebastian, primary, Cai, Shirong, primary, Wu, Xin, primary, Zhou, Yongjian, primary, Tao, Kaixiong, primary, Zheng, Zhichao, primary, Zhang, Jun, primary, Cui, Yuehong, primary, Cao, Hui, primary, Wang, Meining, primary, Hu, Jin, primary, Yang, Jason, primary, Li, Jian, primary, and Shen, Lin, primary

Published
2024
Full Text
View/download PDF

47. Identifying Cell Cycle Modulators That Selectively Target ARID1A Deficiency Using High-Throughput Image-Based Screening

Author

Zhang, Lihong, Shen, Jianfeng, Yin, Yuping, Peng, Yang, Wang, Lulu, Hsieh, Hui-Ju, Shen, Qian, Brown, Powel H, Tao, Kaixiong, Uray, Ivan P, and Peng, Guang

Subjects
Biochemistry and Cell Biology, Biomedical and Clinical Sciences, Biological Sciences, Genetics, Cancer, Biotechnology, Human Genome, 2.1 Biological and endogenous factors, Aetiology, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, ARID1A, FUCCI, cell cycle modulator, high-throughput drug screening, Medicinal & Biomolecular Chemistry, Biochemistry and cell biology, Medical biochemistry and metabolomics, Medical biotechnology
Abstract

ARID1A, a component of the chromatin remodeling complex SWI/SNF, is an evolutionarily conserved complex that uses the energy of adenosine triphosphate hydrolysis to remodel chromatin structure and functions as a master regulator of gene transcription. Recent genomic studies have revealed that ARID1A is one of the most frequently mutated genes in human cancers. However, therapeutic approaches that selectively target ARID1A-mutant tumors are not yet clinically available. Our previous study showed that ARID1A facilitates chromatin response and cell cycle checkpoint activation after DNA damage. Therefore, an ARID1A deficiency may result in therapeutic vulnerabilities in cell cycle modulators. The goals of our study were to develop a novel screening approach, based on fluorescent ubiquitination-based cell cycle indicators (FUCCI), and to identify chemical agents that can selectively modulate the cell cycle transition in ARID1A-deficient cancer cells. Using this high-throughput assay, we screened 2643 compounds and identified six potential chemical modulators that can selectively modulate the cell cycle in ARID1A-deficient cells; these agents may be useful for developing new therapeutics for ARID1A-mutant tumors. In summary, our study demonstrates that FUCCI cell-based high-content screening is a powerful and effective approach for identifying cell cycle modulators and can be applied to multigenotypic screening for targeted cancer therapeutics.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results